Identification of Serum Monocyte Chemoattractant Protein-1 and Prolactin as Potential Tumor Markers in Hepatocellular Carcinoma

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Wang, Who Whong ^a   Ang, Soo Fan ^a   Kumar, Rajneesh ^b   Heah, Charmain ^c   Utama, Andi ^d   Tania, Navessa Padma ^d   Li, Huihua ^b   Tan, Sze Huey ^a   Poo, Desmond ^a   Choo, Su Pin ^a   Chow, Wan Cheng ^b   Tan, Chee Kiat ^b   Toh, Han Chong ^a,c  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

^d Mochtar Riady Institute for Nanotechnology   (Indonesia)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCYTE CHEMOTACTIC PROTEIN 1; PROLACTIN;

ADOLESCENT; ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SURVEILLANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION PROFILING; GENERAL HOSPITAL; HEPATITIS B; HIGH THROUGHPUT SCREENING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; UPREGULATION;

CARCINOMA, HEPATOCELLULAR; CHEMOKINE CCL2; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INDONESIA; LIVER NEOPLASMS; PROLACTIN; PROTEOMICS; ROC CURVE; SINGAPORE; TUMOR MARKERS, BIOLOGICAL;

EID: 84880406738     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068904     Document Type: Article

References (54)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN. Int J Cancer 127: 2893-2917.
2. Bosch FX, Ribes J, Díaz M, Cléries R, (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterol 127: S5-S16.
3. Bismuth H, Majno PE, (2000) Hepatobiliary surgery. J Hepatol 32: 208-224.
4. Llovet JM, Burroughs A, Bruix J, (2003) Hepatocellular carcinoma. Lancet 362: 1907-1917.
5. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, et al. (2001) Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 48: 251-259.
6. Sala M, Varela M, Forner A, Bruix J, (2005) Early diagnosis of liver cancer. Gastroenterol Hepatol 28: 292-297.
7. Collier J, Sherman M, (1998) Screening for hepatocellular carcinoma. Hepatology 27: 273-278.
8. Sherman M, (2001) Alphafetoprotein: an obituary. J Hepatol 34: 603-605.
9. Maringhini A, Cottone M, Sciarrino E, Marceno MP, La Seta F, et al. (1988) Ultrasonography and alpha-fetoprotein in diagnosis of hepatocellular carcinoma in cirrhosis. Dig Dis Sci 33: 47-51.
10. Giannini EG, Marenco S, Borgonovo G, Savarino V, Farinati F, et al. (2012) Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. Hepatology 56: 1371-1379.
11. Chen TH, Chen CJ, Yen MF, Lu SN, Sun CA, et al. (2002) Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. Int J Cancer 98: 257-261.
12. Kobayashi M, Kuroiwa T, Suda T, Tamura Y, Kawai H, et al. (2007) Fucosylated fraction of alpha-fetoprotein, L3, as a useful prognostic factor in patients with hepatocellular carcinoma with special reference to low concentrations of serum alpha-fetoprotein. Hepatol Res 37: 914-922.
13. Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, et al. (2003) Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from non-malignant chronic liver disease in american patients. Hepatology 37: 1114-1121.
14. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, et al. (2009) Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 137: 110-118.
15. Sterling RK, Wright EC, Morgan TR, Seeff LB, Hoefs JC, et al. (2012) Frequency of Elevated Hepatocellular Carcinoma (HCC) Biomarkers in Patients With Advanced Hepatitis C. Am J Gastroenterol. 107: 64-74.
16. Song BC, Chung YH, Kim JA, Choi WB, Suh DD, et al. (2002) Transforming growth factor-beta1 as a useful serologic marker of small hepatocellular carcinoma. Cancer 94: 175-180.
17. Sun S, Poon RT, Lee NP, Yeung C, Chan KL, et al. (2010) Proteomics of hepatocellular carcinoma: serum vimentin as a surrogate marker for small tumors (
18. Chen L, Ho DW, Lee NP, Sun S, Lam B, et al. (2010) Enhanced Detection of Early Hepatocellular Carcinoma by Serum SELDI-TOF Proteomic Signature Combined with Alpha-Fetoprotein Marker. Ann Surg Oncol 17: 2518-2525.
19. Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, et al. (2003) Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 306: 16-25.
20. Miura N, Maeda Y, Kanbe T, Yazama H, Takeda Y, et al. (2005) Serum human telomerase reverse transcriptase messenger RNA as a novel tumor marker for hepatocellular carcinoma. Clin Cancer Res 11: 3205-3209.
21. Llovet JM, Chen Y, Wurmbach E, Roayaie S, Fiel MI, et al. (2006) A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 131: 1758-1767.
22. Jain S, Chen S, Chang KC, Lin YJ, Hu CT, et al. (2012) Impact of the location of CpG methylation within the GSTP1 gene on its specificity as a DNA marker for hepatocellular carcinoma. PLoS One 7: e35789.
23. Shen Q, Fan J, Yang XR, Tan Y, Zhao W, et al. (2012) Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol 13: 817-826.
24. Wulfkuhle JD, Liotta LA, Petricoin EF, (2003) Proteomic applications for the early detection of cancer. Nat Rev Cancer 3: 267-275.
25. Huang R, Jiang W, Yang J, Mao YQ, Zhang Y, et al. (2010) A biotin label-based antibody array for high-content profiling of protein expression. Cancer Genomics Proteomics 7: 129-141.
26. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, et al. (2002) AJCC Cancer Staging Manual 6th Ed. New York: Springer-Verlag. 435 p.
27. Llovet JM, Bru C, Bruix J, (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19: 329-338.
28. Yang B, Zhang B, Xu Y, Wang W, Shen Y, et al. (1997) Prospective study of early detection for primary liver cancer. J Cancer Res Clin Oncol 123: 357-360.
29. Altekruse SF, McGlynn KA, Dickie LA, Kleiner DE, (2012) Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008. Hepatology 55: 476-482.
30. Feng JT, Shang S, Beretta L, (2006) Proteomics for the early detection and treatment of hepatocellular carcinoma. Oncogene 25: 3810-3817.
31. Liotta LA, Espina V, Mehta AI, Calvert V, Rosenblatt K, et al. (2003) Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell 3: 317-325.
32. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, et al. (2010) Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 4: 439-474.
33. Soresi M, Magliarisi C, Campagna P, Leto G, Bonfissuto G, et al. (2003) Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res 23: 1747-1753.
34. Shim JH, Yoon DL, Han S, Lee YJ, Lee SG, et al. (2012) Is serum alpha-fetoprotein useful for predicting recurrence and mortality specific to hepatocellular carcinoma after hepatectomy? A test based on propensity scores and competing risks analysis. Ann Surg Oncol 19: 3687-3696.
35. Sullivan J, Gong Q, Hyslop T, Lavu H, Chipitsyna G, et al. (2011) Serum monocyte chemoattractant protein-1 in pancreatic cancer. J Oncol 2011: 518394.
36. Hefler L, Tempfer C, Heinze G, Mayerhofer K, Breitenecker G, et al. (1999) Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients. Br J Cancer 81: 855-859.
37. Tonouchi H, Miki C, Tanaka K, Kusunoki M, (2002) Profile of monocyte chemoattractant protein-1 circulating levels in gastric cancer patients. Scand J Gastroenterol 37: 830-833.
38. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
39. Dagouassat M, Suffee N, Hlawaty H, Haddad O, Charni F, et al. (2010) Monocyte chemoattractant protein-1 (MCP-1)/CCL2 secreted by hepatic myofibroblasts promotes migration and invasion of human hepatoma cells. Int J Cancer 126: 1095-1108.
40. Friedman SL, (2000) Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 275: 2247-2250.
41. Marra F, DeFranco R, Grappone C, Milani S, Pastacaldi S, et al. (1998) Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am J Pathol 152: 423-430.
42. Antoniades CG, Quaglia A, Taams LS, Mitry RR, Hussain M, et al. (2012) Source and characterization of hepatic macrophages in acetaminophen-induced acute liver failure in humans. Hepatology 56: 735-746.
43. Degré D, Lemmers A, Gustot T, Ouziel R, Trépo E, et al. (2012) Hepatic expression of CCL2 in alcoholic liver disease is associated with disease severity and neutrophil infiltrates. Clin Exp Immunol 169: 302-310.
44. Fisher NC, Neil DA, Williams A, Adams DH, (1999) Serum concentrations and peripheral secretion of the beta chemokines monocyte chemoattractant protein 1 and macrophage inflammatory protein 1alpha in alcoholic liver disease. Gut 45: 416-420.
45. Yoong KF, Afford SC, Jones R, Aujla P, Qin S, et al. (1999) Expression and function of CXC and CC chemokines in human malignant liver tumors: a role for human monokine induced by gamma-interferon in lymphocyte recruitment to hepatocellular carcinoma. Hepatology 30: 100-111.
46. Lin ZY, Chuang YH, Chuang WL, (2012) Cancer-associated fibroblasts up-regulate CCL2, CCL26, IL6 and LOXL2 genes related to promotion of cancer progression in hepatocellular carcinoma cells. Biomed Pharmacother 66: 525-529.
47. Nolen BM, Langmead CJ, Choi S, Lomakin A, Marrangoni A, et al. (2012) Serum biomarker profiles as diagnostic tools in lung cancer. Cancer Biomark 10: 3-12.
48. Bigbee WL, Gopalakrishnan V, Weissfeld JL, Wilson DO, Dacic S, et al. (2012) A multiplexed serum biomarker immunoassay panel discriminates clinical lung cancer patients from high-risk individuals found to be cancer-free by CT screening. J Thorac Oncol 7: 698-708.
49. Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, et al. (2005) Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A 102: 7677-7682.
50. Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, et al. (2008) Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 14: 1065-1072.
51. Hwang J, Na S, Lee H, Lee D, (2009) Correlation between preoperative serum levels of five biomarkers and relationships between these biomarkers and cancer stage in epithelial overian cancer. J Gynecol Oncol 20: 169-175.
52. Buckley AR, Putnam CW, Russell DH, (1985) Prolactin is a tumor promoter in rat liver. Life Sci 37: 2569-2575.
53. García-Caballero T, Mertani HM, Lambert A, Gallego R, Fraga M, et al. (2000) Increased expression of growth hormone and prolactin receptors in hepatocellular carcinomas. Endocrine 12: 265-271.
54. Yeh YT, Lee KT, Tsai CJ, Chen YJ, Wang SN, (2012) Prolactin promotes hepatocellular carcinoma through Janus kinase 2. World J Surg 36: 1128-1135.